Product news

Share this article:

Critical Therapeutics said the FDA has approved the company’s New Drug Application (NDA) for twice-daily Zyflo CR(zileuton) extended-release tablets. Critical Therapeutics, together with its co-promotion partner Dey expect to begin marketing Zyflo CR in the US in the fall of 2007. Zyflo CR and Zyflo (zileuton tablets) are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

 

Upsher-Smith Laboratories received approval from the FDA for the marketing of Divigel (estradiol gel) 0.1 percent -- the lowest approved dose of estradiol available for the treatment of moderate to severe hot flashes associated with menopause.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters